New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
13:43 EDTOREXOrexigen Therapeutics volatility elevated into PDUFA
Orexigen Therapeutics June call option implied volatility is at 164, July is at 116, October is at 88; compared to its 26-week average of 81 according to Track Data, suggesting large movement into the PDUFA goal date of June 10 for Contrave.
News For OREX From The Last 14 Days
Check below for free stories on OREX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
10:03 EDTOREXOrexigen management to meet with Leerink
Meetings to be held in New York on September 23 and in Boston on September 24 hosted by Leerink.
September 17, 2014
07:43 EDTOREXBofA/Merrill to hold a conference
Subscribe for More Information
05:51 EDTOREXStocks with implied volatility movement; OREX MNKD
Stocks with implied volatility movement; Orexigen (OREX) 91, MannKind (MNKD) 60 according to iVolatility.
September 12, 2014
16:44 EDTOREXMarket ends week lower as investors fret over Fed statement
Subscribe for More Information
10:35 EDTOREXOptions with decreasing implied volatility
Subscribe for More Information
September 11, 2014
16:21 EDTOREXOn The Fly: Closing Wrap
Subscribe for More Information
12:42 EDTOREXOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
11:07 EDTOREXOptions with decreasing implied volatility
Subscribe for More Information
10:59 EDTOREXArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
10:49 EDTOREXHigh option volume stocks
Subscribe for More Information
10:29 EDTOREXOrexigen falls, levels to watch
Trading is volatile on very heavy volume nearing three times the daily average. At the current price of $5.41, next support is at $5.30, the low of the day, and then at $4.60 which is the 52-week low. Resistance is at $5.90, the prior session closing price.
08:01 EDTOREXOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
07:06 EDTOREXOrexigen's Contrave weight management tablets approved by FDA
Orexigen Therapeutics and Takeda Pharmaceuticals U.S.A. jointly announced that the FDA has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index indicating obese or overweight, in the presence of at least one weight-related comorbid condition. Takeda is planning to commercially launch Contrave in the fall.
06:49 EDTOREXFDA approves weight management drug Contrave
The U.S. Food and Drug Administration yesterday approved Contrave as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index of 30 or greater or adults with a BMI of 27 or greater who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation. The effectiveness of Contrave was evaluated in multiple clinical trials that included approximately 4,500 obese and overweight patients with and without significant weight-related conditions treated for one year. Contrave is distributed by Takeda Pharmaceuticals America (TKPYY) for Orexigen Therapeutics (OREX).
September 10, 2014
18:27 EDTOREXOrexigen trading halted, pending news
Subscribe for More Information
September 9, 2014
15:27 EDTOREXOrexigen volatility elevated
Subscribe for More Information
12:46 EDTOREXNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
September 8, 2014
17:22 EDTOREXOrexigen, Takeda Pharmaceutical in services agreement
Orexigen disclosed in a regulatory filing that in preparation for the potential launch of NB32, Orexigen Therapeutics (OREX) and Takeda Pharmaceutical Company (TKPYY) entered into a Manufacturing Services Agreement, dated September 2, in accordance with the Collaboration Agreement between the company and Takeda, effective as of September 1, 2010, as amended by Amendment Number 1 to Collaboration Agreement effective as of September 26, 2013. Pursuant to the Agreement, among other things, the company will supply to Takeda, and Takeda will, subject to certain exceptions as set forth in the Agreement and Collaboration Agreement, exclusively purchase from the Company, all of Takeda’s requirements of NB32 for commercialization in the United States, Canada and Mexico during the term of the Collaboration Agreement. The Agreement will continue in full force and effect until the expiration or termination of the Collaboration Agreement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use